Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review

Cancer Causes and Control

Volumn 23, Issue 2, 2012, Pages 221-230

  Mc Menamin, Úna C ^a   Murray, Liam J ^a   Cantwell, Marie M ^a   Hughes, Carmel M ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Cancer progression; Survival; Systematic review

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PROSTATE SPECIFIC ANTIGEN; RAMIPRIL; VALSARTAN; VITAMIN K GROUP;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NEOPLASM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; SURVIVAL;

EID: 84856696117     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-011-9881-x     Document Type: Review

References (39)

1. World Health Organisation (WHO) (2011) Cancer fact sheet No 297. WHO. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed on February 10, 2011
2. T Rosenthal I Gavras 2009 Angiotensin inhibition and malignancies: a review J Hum Hypertens 23 623 635 19339998 10.1038/jhh.2009.21 1:CAS:528:DC%2BD1MXhtFegt7bJ
3. S Greco A Muscella MG Elia, et al. 2003 Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells J Cell Physiol 196 370 377 12811831 10.1002/jcp.10313 1:CAS:528:DC%2BD3sXltlSmtrs%3D (Pubitemid 36775885)
4. K Egami T Murohara T Shimada, et al. 2003 Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth J Clin Invest 112 67 75 12840060 1:CAS:528:DC%2BD3sXlt1Krt7g%3D (Pubitemid 38056377)
5. M Fujita I Hayashi S Yamashina M Itoman M Majima 2002 Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis Biochem Biophys Res 294 441 447 10.1016/S0006-291X(02)00496-5 1:CAS:528:DC%2BD38XktlGrtr4%3D (Pubitemid 34694114)
6. JH Neo C Malcontenti-Wilson V Muralidharan C Christophi 2007 Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases J Gastroenterol Hepatol 22 577 584 17376054 10.1111/j.1440-1746.2006.04797.x 1:CAS:528:DC%2BD2sXmtV2rurw%3D (Pubitemid 46434989)
7. AF Lever DJ Hole CR Gillis, et al. 1998 Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 179 184 9683206 10.1016/S0140-6736(98)03228-0 1:CAS:528:DyaK1cXlt1altbs%3D (Pubitemid 28327802)
8. T Sjöberg LA García Rodríguez M Lindblad 2007 Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study Clin Gastroenterol Hepatol 5 1160 1166 17916544 10.1016/j.cgh.2007.08.005 (Pubitemid 47488980)
9. G Ronquist LA RodrIíguez A Ruigómez, et al. 2004 Association between captopril, other antihypertensive drugs and risk of prostate cancer Prostate 58 50 56 14673952 10.1002/pros.10294 1:CAS:528: DC%2BD2cXpvF2ktg%3D%3D (Pubitemid 38057988)
10. JB Christian KL Lapane AL Hume CB Eaton MA Weinstock 2008 Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial J Natl Cancer Inst 100 1223 1232 18728281 10.1093/jnci/djn262 1:CAS:528:DC%2BD1cXhtFWit7%2FJ
11. CC Huang WL Chan YC Chen, et al. 2011 Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension Am J Cardiol 107 1028 1033 21256465 10.1016/j.amjcard.2010.11.026 1:CAS:528:DC%2BC3MXjs1SksL8%3D
12. CR Meier LE Derby SS Jick H Jick 2000 Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer Arch Intern Med 160 349 353 10668837 10.1001/archinte.160.3.349 1:CAS:528:DC%2BD3cXht1amu7k%3D (Pubitemid 30075217)
13. S Friis HT Sørensen L Mellemkjær, et al. 2001 Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2462 2470 11745304 10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L 1:CAS:528:DC%2BD3MXotl2itbs%3D (Pubitemid 33029093)
14. LH Lindholm H Anderson T Ekbom, et al. 2001 Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial Lancet 358 344 539 10.1016/S0140-6736(01)05704-X (Pubitemid 32772729)
15. B Pasternak H Svanström T Callréus M Melbye A Hviids 2011 Use of angiotensin receptor blockers and the risk of cancer Circulation 123 1729 1736 21482967 10.1161/CIRCULATIONAHA.110.007336 1:CAS:528:DC%2BC3MXltFyhsrk%3D
16. CH Chang JW Lin LC Wu MS Lai 2011 Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study J Clin Oncol 29 3001 3007 21690476 10.1200/JCO.2011.35.1908 1:CAS:528: DC%2BC3MXhtFCqtLbK
17. CI Coleman WL Baker J Kluger CM White 2008 Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials J Hum Hypertens 26 622 629 1:CAS:528: DC%2BD1cXivFOqurk%3D (Pubitemid 351354904)
18. I Sipahi SM Debanne DY Rowland DI Simon JC Fang 2010 Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 627 636 20542468 10.1016/S1470-2045(10)70106-6 1:CAS:528:DC%2BC3cXotVWqu7w%3D
19. Bangalore S, Kumar S, Kjeldsen SE et al. (2010) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncology (Published Online November 30th, 2010)
20. S Connolly S Yusuf K Swedberg On behalf of the ARB Trialists Collaboration, et al. 2011 Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138, 769 individuals J Hypertens 29 623 635
21. F Deshayes C Nahmias 2005 Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16 293 299 16061390 10.1016/j.tem.2005.07.009 1:CAS:528:DC%2BD2MXpsVWhtrs%3D (Pubitemid 41206635)
22. D Moher A Liberati J Tetzlaff DG Altman for the PRISMA Group 2009 Preferred reporting items for systematic reviews, meta-analyses: the PRISMA statement BMJ 339 b2535 19622551 10.1136/bmj.b2535
23. YK Chae ME Valsecchi J Kim, et al. 2011 Reduced risk of breast cancer recurrence in patients using ACI inhibitors, ARBs and/or statins Cancer Invest 29 585 593 21936625 10.3109/07357907.2011.616252 1:CAS:528:DC%2BC3MXhtlGisbrF
24. PA Ganz LA Habel EK Weltzien BJ Caan SW Cole 2011 Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Breast Cancer Res Treat 129 549 556 21479924 10.1007/s10549-011-1505-3 1:CAS:528:DC%2BC3MXpvFyiurk%3D
25. D Keizman P Huang MA Eisenberger, et al. 2001 Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination Eur J Cancer 47 1955 1961 10.1016/j.ejca.2011.04.019
26. A Melhem-Bertrandt M Chavez-MacGregor X Lei, et al. 2011 Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29 2645 2652 21632501 10.1200/JCO.2010.33.4441 1:CAS:528:DC%2BC3MXpvFWltbo%3D
27. Y Nakai H Isayama H Ijichi, et al. 2010 Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine Br J Cancer 103 1644 1648 20978506 10.1038/sj.bjc.6605955 1:CAS:528: DC%2BC3cXhsVygsrvN
28. S Wilop S von Hobe M Crysandt A Esser R Osieka E Jost 2009 Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J Cancer Res Clin Oncol 135 1429 1435 19399518 10.1007/s00432-009-0587-3 1:CAS:528:DC%2BD1MXhtVSitL7N
29. JH Heinzerling T Anthony EH Livingston S Huerta 2007 Predictors of distant metastasis and mortality in patients with stage II colorectal cancer Am Surg 73 230 238 17375777 (Pubitemid 351396700)
30. T Buchler M Krejci A Svobodnik, et al. 2005 Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy Hematol J 5 559 564 15692600 10.1038/sj.thj.6200571 1:CAS:528:DC%2BD2MXjtVGiu78%3D (Pubitemid 40309620)
31. H Yoshiji R Noguchi M Toyohara, et al. 2009 Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma J Hepatol 51 315 321 19501932 10.1016/j.jhep.2009.04. 011 1:CAS:528:DC%2BD1MXnvVams74%3D
32. G Ronquist G Frithz Y Wang T Lindeborg 2009 Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer Scand J Urol Nephrol 43 32 36 18932051 10.1080/00365590802468875 1:CAS:528:DC%2BD1MXotlymsg%3D%3D
33. H Lindberg D Nielsen BV Jensen J Eriksen T Skovsgaard 2004 Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 43 142 152 15163162 10.1080/02841860310022346 1:CAS:528:DC%2BD2cXktFGkurc%3D (Pubitemid 38478900)
34. D Herr M Rodewald HM Fraser, et al. 2008 Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer Gynecol Oncol 109 418 425 18395779 10.1016/j.ygyno.2008.02.019 1:CAS:528:DC%2BD1cXmvVKrsb4%3D
35. SP Blagden SC Charman LD Sharples LRA Magee D Gilligan 2003 Performance status score: do patients and their oncologists agree? Br J Cancer 89 1022 1027 12966419 10.1038/sj.bjc.6601231 1:STN:280:DC%2BD3svisVKquw%3D%3D (Pubitemid 37239205)
36. BB Barone HC Yeh CF Snyder, et al. 2008 Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis JAMA 300 2754 2764 19088353 10.1001/jama.2008.824 1:CAS:528:DC%2BD1cXhsFalur%2FP
37. A McTiernan M Irwin V VonGruenigen 2010 Weight, physical activity, diet, and prognosis in breast and gynecologic cancers J Clin Oncol 28 4074 4080 20644095 10.1200/JCO.2010.27.9752
38. EE Calle C Rodriguez K Walker-Thurmond MJ Thun 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults N Engl J Med 348 1625 1638 12711737 10.1056/NEJMoa021423 (Pubitemid 36459468)
39. Morrison, DS, Batty GD, Kivimaki M, Smith GD, Marmot M, Shipley M (2006) Risk factors for colonic and rectal cancer mortality: evidence from 40 years' follow-up in the Whitehall I study. J Epidemiol Community Health (Published online March 9th, 2006)